Es gab 50 kürzliche Insider-Transaktionen für Arrowhead Pharmaceuticals, Inc. (ARWR), darunter 13 Käufe und 33 Verkäufe. Die gesamten Insider-Käufe beliefen sich auf $963.33K und die gesamten Insider-Verkäufe auf $12.5M.
Bedeutende Insider mit kürzlicher Aktivität umfassen Hamilton James C, O'brien Patrick, Apel Daniel Joseph. Insider-Transaktionen können Einblicke geben, wie die Unternehmensführung die Bewertung und Zukunftsaussichten der Aktie einschätzt.
Insider-Transaktionen — ARWR
| Datum |
Name |
Funktion |
Transaktionsart |
Aktien |
Ø Preis |
Wert |
Gehaltene Aktien |
| 2026-03-05 |
Hamilton James C |
Chief Medical Officer |
Informierter Verkauf |
10,000 |
$64.19 |
$641.9K |
236,958 |
| 2026-01-06 |
O'brien Patrick |
COO |
Schenkung (gegeben) |
440 |
- |
- |
472,408 |
| 2026-01-06 |
Hamilton James C |
Chief Medical Officer |
RSU-Zuteilung |
75,000 |
- |
- |
246,958 |
| 2026-01-06 |
Apel Daniel Joseph |
Chief Financial Officer |
RSU-Zuteilung |
75,000 |
- |
- |
176,200 |
| 2026-01-05 |
O'brien Patrick |
COO |
Informierter Verkauf |
46 |
$68.00 |
$3.13K |
474,908 |
| 2026-01-05 |
Hamilton James C |
Chief Medical Officer |
Informierter Verkauf |
309 |
$68.00 |
$21.01K |
171,958 |
| 2026-01-02 |
Anzalone Christopher Richard |
Chief Executive Officer |
Informierter Verkauf |
5,771 |
$66.39 |
$383.14K |
3,792,739 |
| 2025-12-31 |
O'brien Patrick |
COO |
Schenkung (gegeben) |
560 |
- |
- |
524,401 |
| 2025-12-29 |
Anzalone Christopher Richard |
Chief Executive Officer |
Optionsausübung (Verkauf) |
16,545 |
$6.15 |
$101.75K |
- |
| 2025-12-26 |
Ferrari Mauro |
Director |
Informierter Verkauf |
7,530 |
$70.00 |
$527.1K |
69,053 |
| 2025-12-22 |
Anzalone Christopher Richard |
Chief Executive Officer |
Informierter Verkauf |
2,574 |
$68.85 |
$177.22K |
3,805,926 |
| 2025-12-19 |
Olukotun Adeoye Y |
Director |
Informierter Verkauf |
827 |
$68.48 |
$56.63K |
33,600 |
| 2025-12-19 |
Anzalone Christopher Richard |
Chief Executive Officer |
Informierter Verkauf |
1,319 |
$68.48 |
$90.33K |
3,818,512 |
| 2025-12-19 |
Waddill William D. |
Director |
Informierter Verkauf |
500 |
$68.53 |
$34.27K |
56,563 |
| 2025-12-19 |
Vakiener Victoria |
Director |
Informierter Verkauf |
1,960 |
$68.39 |
$134.04K |
35,723 |
| 2025-12-17 |
Anzalone Christopher Richard |
Chief Executive Officer |
Informierter Verkauf |
1,981 |
$66.30 |
$131.34K |
3,831,957 |
| 2025-12-16 |
Anzalone Christopher Richard |
Chief Executive Officer |
Informierter Verkauf |
3,221 |
$67.87 |
$218.61K |
3,916,957 |
| 2025-12-16 |
Ingram Douglas S |
Director |
RSU-Zuteilung |
7,819 |
- |
- |
46,215 |
| 2025-12-16 |
Olukotun Adeoye Y |
Director |
RSU-Zuteilung |
7,819 |
- |
- |
43,600 |
| 2025-12-16 |
Perry Michael S |
Director |
RSU-Zuteilung |
7,819 |
- |
- |
123,059 |
| 2025-12-16 |
Ferrari Mauro |
Director |
RSU-Zuteilung |
7,819 |
- |
- |
76,583 |
| 2025-12-16 |
Waddill William D. |
Director |
RSU-Zuteilung |
7,819 |
- |
- |
64,930 |
| 2025-12-16 |
Lu Hongbo |
Director |
RSU-Zuteilung |
7,819 |
- |
- |
54,982 |
| 2025-12-16 |
Vakiener Victoria |
Director |
RSU-Zuteilung |
7,819 |
- |
- |
45,763 |
| 2025-12-15 |
Anzalone Christopher Richard |
Chief Executive Officer |
Informierter Verkauf |
8,147 |
$69.96 |
$569.96K |
3,971,255 |
| 2025-12-12 |
Anzalone Christopher Richard |
Chief Executive Officer |
RSU-Zuteilung |
180,000 |
- |
- |
4,101,255 |
| 2025-12-05 |
Perry Michael S |
Director |
Informierter Verkauf |
16,250 |
$61.03 |
$991.74K |
115,240 |
| 2025-11-28 |
Ferrari Mauro |
Director |
Informierter Verkauf |
8,750 |
$56.39 |
$493.41K |
68,764 |
| 2025-10-01 |
Hamilton James C |
Chief Medical Officer |
Informierter Verkauf |
20,000 |
$35.00 |
$700K |
212,122 |
| 2025-09-12 |
Hamilton James C |
Chief Medical Officer |
Informierter Verkauf |
15,000 |
$30.00 |
$450K |
232,122 |
| 2025-09-02 |
Hamilton James C |
Chief Medical Officer |
Informierter Verkauf |
15,000 |
$25.00 |
$375K |
247,122 |
| 2025-08-15 |
Hamilton James C |
Chief Medical Officer |
Informierter Verkauf |
9,389 |
$20.00 |
$187.78K |
262,122 |
| 2025-08-13 |
Hamilton James C |
Chief Medical Officer |
Informierter Verkauf |
611 |
$20.00 |
$12.22K |
271,511 |
| 2025-04-15 |
Apel Daniel Joseph |
Chief Financial Officer |
Unbekannt |
- |
- |
- |
101,200 |
| 2025-04-11 |
Anzalone Christopher Richard |
Chief Executive Officer |
Informierter Verkauf |
50,800 |
$11.49 |
$583.69K |
3,921,255 |
| 2025-04-10 |
Anzalone Christopher Richard |
Chief Executive Officer |
Informierter Verkauf |
50,000 |
$10.87 |
$543.5K |
3,972,055 |
| 2025-04-09 |
Anzalone Christopher Richard |
Chief Executive Officer |
Informierter Verkauf |
1,617 |
$11.76 |
$19.02K |
4,022,055 |
| 2025-03-13 |
Anzalone Christopher Richard |
Chief Executive Officer |
Informierter Verkauf |
51,425 |
$15.07 |
$774.97K |
4,062,377 |
| 2025-03-04 |
Anzalone Christopher Richard |
Chief Executive Officer |
Informierter Verkauf |
133,333 |
$17.02 |
$2.27M |
3,773,802 |
| 2025-03-03 |
Anzalone Christopher Richard |
Chief Executive Officer |
Optionsausübung (Verkauf) |
133,333 |
$7.75 |
$1.03M |
51,726 |
| 2025-02-07 |
Anzalone Christopher Richard |
Chief Executive Officer |
RSU-Zuteilung |
9,550 |
$20.10 |
$191.96K |
3,773,802 |
| 2025-02-06 |
Ingram Douglas S |
Director |
Unbekannt |
- |
- |
- |
- |
| 2025-02-06 |
Ingram Douglas S |
Director |
RSU-Zuteilung |
38,396 |
$20.09 |
$771.38K |
38,396 |
| 2025-01-23 |
Olukotun Adeoye Y |
Director |
Informierter Verkauf |
959 |
$21.00 |
$20.14K |
35,781 |
| 2025-01-07 |
Myszkowski Kenneth Allen |
Chief Financial Officer |
Informierter Verkauf |
10,000 |
$19.69 |
$196.9K |
455,433 |
| 2025-01-07 |
O'brien Patrick |
COO and General Counsel |
Informierter Verkauf |
8,000 |
$19.69 |
$157.52K |
527,201 |
| 2025-01-06 |
Myszkowski Kenneth Allen |
Chief Financial Officer |
Informierter Verkauf |
9,402 |
$20.10 |
$188.98K |
473,433 |
| 2025-01-06 |
O'brien Patrick |
COO and General Counsel |
Informierter Verkauf |
9,526 |
$20.10 |
$191.47K |
535,201 |
| 2025-01-06 |
Hamilton James C |
Chief Discovery/trans Medicine |
Informierter Verkauf |
10,971 |
$20.11 |
$220.63K |
272,122 |
| 2025-01-04 |
Myszkowski Kenneth Allen |
Chief Financial Officer |
RSU-Zuteilung |
100,000 |
- |
- |
500,600 |
■ Informativ — Transaktion am offenen Markt (bedeutendste)
■ Nicht-informativ (Kauf) — Vergütung, Optionsausübung, Wandlung
■ Nicht-informativ (Verkauf) — Quellensteuer, Verkauf bei Vesting
■ Neutral — Schenkung, Treuhand, Verfall
